Phase 3 trial of everolimus for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Phase 3 trial of everolimus for metastatic renal cell carcinoma

Published:2010-08-19 Issue:18 Volume:116 Page:4256-4265
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Motzer Robert J.,Escudier Bernard,Oudard Stephane,Hutson Thomas E.,Porta Camillo,Bracarda Sergio,Grünwald Viktor,Thompson John A.,Figlin Robert A.,Hollaender Norbert,Kay Andrea,Ravaud Alain

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25219/fullpdf

Reference15 articles.

1. TSC2 regulates VEGF through mTOR-dependent and -independent pathways;Brugarolas;Cancer Cell.,2003

2. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer;Thomas;Nat Med.,2006

3. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet.,2008

4. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol.,2004

5. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst.,2000

Cited by 1057 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The treatment of metastatic renal cell carcinoma;Deutsches Ärzteblatt international;2024-08-23

2. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma;New England Journal of Medicine;2024-08-22

3. Inhibitory effects of the combination of rapamycin with gemcitabine plus paclitaxel on the growth of pancreatic cancer tumors;2024-08-22

4. Methuosis Inducer SGI‐1027 Cooperates with Everolimus to Promote Apoptosis and Pyroptosis by Triggering Lysosomal Membrane Permeability in Renal Cancer;Advanced Science;2024-08-09

5. Renal cell carcinoma;The Lancet;2024-08